Published in Clin Cancer Res on April 01, 2007
Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res (2007) 1.25
Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells. BMC Cancer (2010) 0.82
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49
Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med (2005) 2.94
Clinical applications of metabolomics in oncology: a review. Clin Cancer Res (2009) 2.91
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res (2004) 2.79
Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol (2007) 2.70
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol (2008) 2.57
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol (2011) 2.43
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol (2009) 2.36
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol (2004) 2.13
Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes (2005) 2.12
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.96
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
Lung cancer screening: is it time for a change in policy? Cleve Clin J Med (2007) 1.93
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res (2007) 1.89
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence. Am J Surg Pathol (2009) 1.84
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood (2008) 1.71
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 1.66
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood (2007) 1.65
CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem (2008) 1.65
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res (2005) 1.65
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol (2006) 1.61
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res (2010) 1.56
Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. Thorax (2007) 1.54
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst (2008) 1.53
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52
Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer (2005) 1.52
Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health (2007) 1.45
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 1.43
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem (2004) 1.43
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol (2006) 1.39
A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet (2010) 1.38
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res (2008) 1.36
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res (2006) 1.33
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res (2009) 1.33
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res (2007) 1.32
NMR-based metabolomics: translational application and treatment of cancer. Curr Opin Mol Ther (2007) 1.30
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol (2009) 1.30
AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist (2013) 1.29
ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood (2006) 1.27
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol (2012) 1.26
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem (2002) 1.22
A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol (2009) 1.22
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer (2004) 1.20
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther (2010) 1.19
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J Thorac Oncol (2012) 1.19
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs (2010) 1.16
Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol (2008) 1.15
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res (2010) 1.15
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res (2007) 1.14
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol (2014) 1.14
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res (2009) 1.12
Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg (2005) 1.11
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther (2005) 1.11
Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract (2008) 1.09
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res (2007) 1.09
S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer (2005) 1.09
Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol Pharmacol (2002) 1.07
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res (2002) 1.07
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol (2007) 1.07
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther (2009) 1.07
Co-evolving motions at protein-protein interfaces of two-component signaling systems identified by covariance analysis. Biochemistry (2008) 1.06
Clinical use of electrogustometry: strengths and limitations. Acta Otolaryngol Suppl (2002) 1.04
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol (2009) 1.04
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res (2013) 1.03
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer (2010) 1.02
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res (2010) 1.02
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res (2009) 1.02
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res (2011) 1.02